Gestational Trophoblastic Disease Clinical Trial
Official title:
Camrelizumab Combined With Apatinib for Recurrent Resistant Gestational Trophoblastic Neoplasia: a Phase 2, Single-arm, Prospective Study
This study is to evaluate the efficacy and safety of camrelizumab plus apatinib in patients with high-risk chemo-refractory or relapsed GTN.
Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2. Novel immunotherapy using the immune checkpoint inhibitors such as anti-PD-1 antibody has received much attention. Camrelizumab as one of the anti-PD-1 drug have impressive clinical activity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03280979 -
Rescue Regimen and High Dose Methotrexate in Management of Presistent Gestational Trophoplastic Neoplasia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02892877 -
The French National Reference Centre of GTD
|
N/A | |
| Completed |
NCT00706875 -
A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors
|
||
| Active, not recruiting |
NCT05203562 -
Letrozole as a Prophylaxis From GTN for Complete Mole Patients
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05635344 -
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
|
Phase 2 | |
| Active, not recruiting |
NCT01823315 -
Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia
|
Phase 3 | |
| Recruiting |
NCT06339827 -
ASk Questions in GYnecologic Oncology (ASQ-GYO)
|
N/A |